Pediatric Blood & Cancer

Papers
(The TQCC of Pediatric Blood & Cancer is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The COVID‐19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP‐E, SIOP‐PODC, IPSO, PROS, CCI, and St Jude Global99
Osteosarcoma94
COVID‐19 infection in children and adolescents with cancer in Madrid90
Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experience78
COVID‐19 and children with cancer: Parents’ experiences, anxieties and support needs73
Children with cancer in the time of COVID‐19: An 8‐week report from the six pediatric onco‐hematology centers in Lombardia, Italy72
COVID‐19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?68
Neuroblastoma62
Delayed cancer diagnoses and high mortality in children during the COVID‐19 pandemic58
Hematological manifestations of SARS‐CoV‐2 in children55
COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)52
COVID‐19 anticoagulation recommendations in children50
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis50
2023 ASPHO Conference Paper and Poster Index46
Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review45
COVID‐19 disease in New York City pediatric hematology and oncology patients44
ABSTRACTS41
Impacts of COVID‐19 on caregivers of childhood cancer survivors41
Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia41
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials40
A collateral effect of the COVID‐19 pandemic: Delayed diagnosis in pediatric solid tumors39
Wilms tumor38
Ewing sarcoma38
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studi37
A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups35
Late effects of radiation therapy in pediatric patients and survivorship35
No increase in psychosocial stress of Dutch children with cancer and their caregivers during the first months of the COVID‐19 pandemic34
Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase33
Internet‐delivered insomnia intervention improves sleep and quality of life for adolescent and young adult cancer survivors33
Children and young adults hospitalized for severe COVID‐19 exhibit thrombotic coagulopathy33
ABSTRACTS33
Convalescent plasma for pediatric patients with SARS‐CoV‐2‐associated acute respiratory distress syndrome32
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS‐CoV‐2 pandemic32
Rare non‐Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric‐type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T‐ce32
ORAL ABSTRACTS32
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B‐acute lymphoblastic leukemia31
SIOP ABSTRACTS31
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project30
SARS‐CoV‐2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic30
COVID‐19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation29
A prospective study on the long‐term outcome of prepubertal and pubertal boys undergoing testicular biopsy for fertility preservation prior to hematologic stem cell transplantation29
Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia28
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database27
Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients27
COVID‐19 in pediatric cancer patients in a resource‐limited setting: National data from Peru27
Severe adverse events during sirolimus “off‐label” therapy for vascular anomalies27
Collateral effects of COVID‐19 pandemic in pediatric hematooncology: Fatalities caused by diagnostic delay27
Sarcopenia is a prognostic outcome marker in children with high‐risk hepatoblastoma26
Acute lymphoblastic leukemia26
Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐00126
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial26
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project26
Tools to guide the identification and implementation of care consistent with the psychosocial Standards of care25
SIOP ABSTRACTS25
Barriers and enablers to physical activity and aerobic fitness deficits among childhood cancer survivors24
PediCARE: Development of a poverty‐targeted intervention for pediatric cancer24
The role of diffusion tensor imaging metrics in the discrimination between cerebellar medulloblastoma and brainstem glioma24
Long‐term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study24
The gut microbiome in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation24
Pediatric cancer research: Surviving COVID‐1924
Second tumor risk in children treated with proton therapy24
Improvement of overall survival in the Collaborative Wilms Tumour Africa Project24
Frequency of face touching with and without a mask in pediatric hematology/oncology health care professionals23
Homestead together: Pediatric palliative care telehealth support for rural children with cancer during home‐based end‐of‐life care23
Sickle cell disease and COVID‐19: Susceptibility and severity23
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma23
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042)23
How we approach the diagnosis and management of complex lymphatic anomalies22
How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C22
Guidance regarding COVID‐19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group22
Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission21
Feasibility of FitSurvivor: A technology‐enhanced group‐based fitness intervention for adolescent and young adult survivors of childhood cancer21
Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience21
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research21
Long‐term health‐related quality of life in young childhood cancer survivors and their parents21
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years21
Brain tumors: Medulloblastoma, ATRT, ependymoma21
Delayed presentations of pediatric solid tumors at a tertiary care hospital in the Bronx due to COVID‐1920
Benign course of SARS‐CoV‐2 infection in a series of pediatric oncology patients20
COVID‐19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study20
Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors20
Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience20
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease20
Long‐term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy19
Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin‐2 levels19
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group19
Virtual visits as long‐term follow‐up care for childhood cancer survivors: Patient and provider satisfaction during the COVID‐19 pandemic19
Household material hardships impact emergency department reliance in pediatric patients with sickle cell disease19
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom19
Rhabdomyosarcoma19
Epidemiology and survival of childhood cancer in Turkey18
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pedia18
Discrepancies between F‐18‐FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis18
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?18
Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft‐Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studie18
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low‐grade glioma18
Undifferentiated sarcoma of the liver: Multicenter international experience of the Cooperative Soft‐Tissue Sarcoma Group and Polish Paediatric Solid Tumor Group18
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy–induced vomiting in children: An open‐label, randomized phase 3 trial18
The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders18
Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi18
Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations18
Why do young people get cancer?18
A randomized controlled trial of a structured exercise intervention after the completion of acute cancer treatment in adolescents and young adults18
18F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis18
COVID‐19 infection in febrile neutropenic pediatric hematology oncology patients17
Assessment of nutritional status in children with cancer: Significance of arm anthropometry and serum visceral proteins17
Clinical prognostic factors in pediatric adrenocortical tumors: A meta‐analysis17
Impact of COVID‐19 on adolescent and emerging adult brain tumor survivors and their parents17
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma17
Ruxolitinib in children with steroid‐refractory acute graft‐versus‐host disease: A retrospective multicenter study of the pediatric group of SFGM‐TC17
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)16
Care experiences that foster trust between parents and physicians of children with cancer16
A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high‐risk pediatric patients16
Treatment of central giant cell granuloma in children with denosumab16
A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study16
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab16
COVID‐19 and childhood acute lymphoblastic leukemia16
Treatment of acute myeloid leukemia in children: A practical perspective16
Interdependent functions of communication with adolescents and young adults in oncology16
The role of twinning in sustainable care for children with cancer: A TIPPing point? SIOP PODC Working Group on Twinning, Collaboration, and Support16
A review of the experience with pediatric written requests issued for oncology drug products16
Whole‐body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update16
Successful use of transarterial radioembolization with yttrium‐90 (TARE‐Y90) in two children with hepatoblastoma16
Implementation of daily patient‐reported outcome measurements to support children with cancer16
Severe COVID‐19 disease in two pediatric oncology patients15
Safety and efficacy of gamma‐secretase inhibitor nirogacestat (PF‐03084014) in desmoid tumor: Report of four pediatric/young adult cases15
A Saudi family with sickle cell disease presented with acute crises and COVID‐19 infection15
Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia15
SARS‐CoV‐2 disease and children under treatment for cancer15
Acute chest syndrome in the setting of SARS‐COV‐2 infections—A case series at an urban medical center in the Bronx15
Oncology care in a lower middle‐income country during the COVID‐19 pandemic15
Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy15
Effects of hydroxyurea on brain function in children with sickle cell anemia15
Mucosal barrier injury–associated bloodstream infections in pediatric oncology patients15
Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study15
Incidence and 5‐year survival of children and adolescents with hepatoblastoma in the United States15
Sickle cell disease and social determinants of health: A scoping review15
Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation15
Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of personal payments from pharmaceutical co15
Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study15
Introducing INSTRuCT: An international effort to promote cooperation and data sharing15
A community‐based trial of a psychosocial eHealth intervention for parents of children with cancer15
Treatment abandonment: A report from the collaborative African network for childhood cancer care and research—CANCaRe Africa14
In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consor14
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review14
Social determinants of health and pediatric cancer survival: A systematic review14
Screening for SARS‐CoV‐2 infection in pediatric oncology patients during the epidemic peak in Italy14
How we approach malignant infantile osteopetrosis14
Clinical evaluation of late outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER 2 study14
Delivering pediatric oncology services during a COVID‐19 pandemic in India14
Pseudohypoxic pheochromocytomas and paragangliomas dominate in children14
L‐leucine improves anemia and growth in patients with transfusion‐dependent Diamond‐Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond‐Blackfan Anemia Registry14
The importance of enteral nutrition to prevent or treat undernutrition in children undergoing treatment for cancer14
“Living life as if I never had cancer”: A study of the meaning of living well in adolescents and young adults who have experienced cancer14
Factors affecting COVID‐19 vaccine hesitancy in parents of children with cancer14
Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents14
Prevention of acute and delayed chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline14
Palliative care considerations and practices for adolescents and young adults with cancer14
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children13
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune‐suppressive therapy for newly diagnosed 13
Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups13
Abstracts for PBC Volume 67, Supplement 513
A pilot study of the preliminary efficacy of Pain Buddy: A novel intervention for the management of children's cancer‐related pain13
A single supratentorial high‐grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival13
Acute lymphoblastic leukemia onset in a 3‐year‐old child with COVID‐1913
Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors13
Much is left unspoken: Self‐reports from families in pediatric oncology13
Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents13
Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs13
SARS‐CoV‐2 in children with cancer in Brazil: Results of a multicenter national registry13
Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib13
Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer13
The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor13
Family functioning and adaptation following pediatric brain tumor: A systematic review13
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup f13
Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects13
COVID‐19 and childhood acute lymphoblastic leukemia13
The state of the science for communication training in pediatric oncology: A systematic review13
The annual incidence of Langerhans cell histiocytosis among adults living in Greece13
Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescent13
Defining palliative opportunities in pediatric patients with bone and soft tissue sarcomas13
Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia13
Clinical impact of hypothalamic‐pituitary disorders after conformal radiation therapy for pediatric low‐grade glioma or ependymoma13
Reducing acute kidney injury in pediatric oncology patients: An improvement project targeting nephrotoxic medications13
Psychological adjustment outcomes among pediatric brain tumor survivors: A meta‐analysis13
Radiologic response to MEK inhibition in a patient with a WNT‐activated craniopharyngioma12
Evaluation of the nephron‐sparing surgery formula in Wilms tumors12
Racial and ethnic disparities in survival of children with brain and central nervous tumors in the United States12
Acceptability and feasibility of survivorship care plans and an accompanying mobile health intervention for adolescent and young adult survivors of childhood cancer12
Hematological parameters and peripheral blood morphologic abnormalities in children with COVID‐1912
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective12
Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, the European Pediatric Soft‐Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom S12
“Money was the problem”: Caregivers' self‐reported reasons for abandoning their children's cancer treatment in southwest Uganda12
A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib12
Comparison of neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low‐grade astrocytoma, and healthy controls12
Pediatric classical Hodgkin lymphoma12
Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study)12
Eltrombopag in children with severe aplastic anemia12
Prevention and treatment of anticipatory chemotherapy‐induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update12
Long‐term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan12
Childhood cancer survivorship and late effects: The landscape in India in 202012
Paratesticular rhabdomyosarcoma—Impact of locoregional approach on patient outcome: A report from the European paediatric Soft tissue sarcoma Study Group (EpSSG)12
Cranial polyneuropathy as the first manifestation of a severe COVID‐19 in a child12
Pediatric and young adult renal cell carcinoma12
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium12
Solitary serum methotrexate level 36 hours post high‐dose methotrexate: A safe, efficacious, and cost‐effective strategy to monitor methotrexate toxicities in childhood leukemia in resource‐limited ce12
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6‐mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestina12
Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: Results and lessons learned12
Wilms tumor in Africa: A systematic review of management challenges and outcome in two decades (2000‐2019)12
Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP)12
Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations12
High mortality of COVID‐19 in children with cancer in a single center in Algiers, Algeria12
Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10‐year review12
Children with cancer during COVID‐19 pandemic: Early experience in Mexico11
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity11
Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low‐resource settings11
Health support to pediatric cancer survivors and their families during the COVID‐19 pandemic11
Integrating irinotecan in standard chemotherapy: A novel dose‐density combination for high‐risk pediatric sarcomas11
Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia11
Socioeconomic disparities in survival after high‐risk neuroblastoma treatment with modern therapy11
Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)11
Daratumumab in T‐cell acute lymphoblastic leukaemia: A case report and review of the literature11
Long‐term results from the multicentric European randomized phase 3 trial CWS/RMS‐96 for localized high‐risk soft tissue sarcoma in children, adolescents, and young adults11
Nutritional traditional and complementary medicine strategies in pediatric cancer: A narrative review11
Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia11
Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia11
Prospective randomized trial of interventions for vincristine‐related neuropathic pain11
The intersectionality of gender and poverty on symptom suffering among adolescents with cancer11
Nocturnal hypertension associated with stroke and silent cerebral infarcts in children with sickle cell disease11
Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real‐world setting: Results from the NEUF study11
Clinicopathological study of surgery for pulmonary metastases of hepatoblastoma with indocyanine green fluorescent imaging11
SARS‐CoV‐2 persistence in immunocompromised children11
The European Paediatric Rare Tumours Network ‐ European Registry (PARTNER) project for very rare tumors in children11
How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group11
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma11
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study11
Cognitive functioning, patient health communication, and worry mediate pain predictive effects on health‐related quality of life in youth with sickle cell disease11
Abstracts from the 38th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Stockholm, Sweden from September 18‐20, 202211
The COVID‐19 pandemic: Distance‐delivered care for childhood cancer survivors11
Oral processing speed as a key mechanism in the relationship between neurological risk and adaptive functioning in survivors of pediatric brain tumors11
Practice patterns and recommendations for pediatric image‐guided radiotherapy: A Children's Oncology Group report11
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS)11
Parent perceptions of pediatric oncology care during the COVID‐19 pandemic: An Australian study11
Unresectable thoracic neuroblastic tumors: Changes in image‐defined risk factors after chemotherapy and impact on surgical management11
Neuropathic pain is associated with poor health‐related quality of life in adolescents with sickle cell disease: A preliminary report11
Improving self‐management in adolescents with sickle cell disease10
Nasopharyngeal carcinoma in children and young adults—Beyond 5‐year survival10
Coronavirus disease 2019 3 months after hematopoietic stem cell transplant: A pediatric case report10
Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low‐risk clinical trials: A report from the Children's Oncology Group10
Daily text message assessments of 6‐mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study10
0.069918870925903